Levorphanol
| Clinical data | |
|---|---|
| Trade names | Levo-Dromoran | 
| Other names | Ro 1-5431 | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682020 | 
| Routes of administration | Oral, intravenous, subcutaneous, intramuscular | 
| ATC code | 
 | 
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | 70% (oral); 100% (IV) | 
| Protein binding | 40% | 
| Metabolism | Hepatic | 
| Elimination half-life | 11–16 hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.912 | 
| Chemical and physical data | |
| Formula | C17H23NO | 
| Molar mass | 257.377 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Levorphanol (brand name Levo-Dromoran) is an opioid medication used to treat moderate to severe pain. It is the levorotatory enantiomer of the compound racemorphan. Its dextrorotatory counterpart is dextrorphan.
It was first described in Germany in 1946. The drug has been in medical use in the United States since 1953.